Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against ...
Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that ...
Though barzolvolimab displayed what one analyst described as the best efficacy results to date against chronic skin hives, ...
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results